Article
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Human pathology - 1 May 2007
Hornick Jason L, Fletcher Christopher D M
Abstract excerpt
In recent years, immunohistochemical staining for KIT (CD117) has become integral to the diagnosis of gastrointestinal stromal tumors (GISTs), nearly 90% of which harbor activating mutations in the KIT receptor tyrosine kinase gene. Approximately 80% of patients with metastatic GIST show at least some clinical response to the targeted small molecule KIT inhibitor imatinib. The response to imatinib is closely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.